Display options
Cite
Koizumi H, Goto S, Okita S, et al. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2. Front Neurol. 2014;5:98doi: 10.3389/fneur.2014.00098.
Koizumi, H., Goto, S., Okita, S., Morigaki, R., Akaike, N., Torii, Y., Harakawa, T., Ginnaga, A., & Kaji, R. (2014). Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2. Frontiers in neurology, 598. https://doi.org/10.3389/fneur.2014.00098
Koizumi, Hidetaka, et al. "Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2." Frontiers in neurology vol. 5 (2014): 98. doi: https://doi.org/10.3389/fneur.2014.00098
Koizumi H, Goto S, Okita S, Morigaki R, Akaike N, Torii Y, Harakawa T, Ginnaga A, Kaji R. Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2. Front Neurol. 2014 Jun 23;5:98. doi: 10.3389/fneur.2014.00098. eCollection 2014. PMID: 25002857; PMCID: PMC4066301.
Copy Download .nbib Format: NLM
Share it on

Front Neurol. 2014 Jun 23;5:98. doi: 10.3389/fneur.2014.00098. eCollection 2014.

Spinal Central Effects of Peripherally Applied Botulinum Neurotoxin A in Comparison between Its Subtypes A1 and A2.

Frontiers in neurology

Hidetaka Koizumi, Satoshi Goto, Shinya Okita, Ryoma Morigaki, Norio Akaike, Yasushi Torii, Tetsuhiro Harakawa, Akihiro Ginnaga, Ryuji Kaji

Affiliations

  1. Department of Clinical Neuroscience, Institute of Health Biosciences, Graduate School of Medical Sciences, University of Tokushima , Tokushima , Japan ; Department of Motor Neuroscience and Neurotherapeutics, Institute of Health Biosciences, Graduate School of Medical Sciences, University of Tokushima , Tokushima , Japan.
  2. Department of Motor Neuroscience and Neurotherapeutics, Institute of Health Biosciences, Graduate School of Medical Sciences, University of Tokushima , Tokushima , Japan.
  3. Research Division for Life Science, Kumamoto Health Science University , Kumamoto , Japan.
  4. The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN) , Kumamoto , Japan ; Graduate School of Medicine, Osaka University , Osaka , Japan.
  5. The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN) , Kumamoto , Japan.
  6. Department of Clinical Neuroscience, Institute of Health Biosciences, Graduate School of Medical Sciences, University of Tokushima , Tokushima , Japan.

PMID: 25002857 PMCID: PMC4066301 DOI: 10.3389/fneur.2014.00098

Abstract

Because of its unique ability to exert long-lasting synaptic transmission blockade, botulinum neurotoxin A (BoNT/A) is used to treat a wide variety of disorders involving peripheral nerve terminal hyperexcitability. However, it has been a matter of debate whether this toxin has central or peripheral sites of action. We employed a rat model in which BoNT/A1 or BoNT/A2 was unilaterally injected into the gastrocnemius muscle. On time-course measurements of compound muscle action potential (CMAP) amplitudes after injection of BoNT/A1 or BoNT/A2 at doses ranging from 1.7 to 13.6 U, CMAP amplitude for the ipsilateral hind leg was markedly decreased on the first day, and this muscle flaccidity persisted up to the 14th day. Of note, both BoNT/A1 and BoNT/A2 administrations also resulted in decreased CMAP amplitudes for the contralateral leg in a dose-dependent manner ranging from 1.7 to 13.6 U, and this muscle flaccidity increased until the fourth day and then slowly recovered. Immunohistochemical results revealed that BoNT/A-cleaved synaptosomal-associated protein of 25 kDa (SNAP-25) appeared in the bilateral ventral and dorsal horns 4 days after injection of BoNT/A1 (10 U) or BoNT/A2 (10 U), although there seemed to be a wider spread of BoNT/A-cleaved SNAP-25 associated with BoNT/A1 than BoNT/A2 in the contralateral spinal cord. This suggests that the catalytically active BoNT/A1 and BoNT/A2 were axonally transported via peripheral motor and sensory nerves to the spinal cord, where they spread through a transcytosis (cell-to-cell trafficking) mechanism. Our results provide evidence for the central effects of intramuscularly administered BoNT/A1 and BoNT/A2 in the spinal cord, and a new insight into the clinical effects of peripheral BoNT/A applications.

Keywords: SNAP-25; axonal transport; botulinum neurotoxin; central effects; spinal cord

References

  1. Neurology. 2008 May 6;70(19):1699-706 - PubMed
  2. Physiol Rev. 2000 Apr;80(2):717-66 - PubMed
  3. J Neurochem. 2009 Apr;109(1):15-24 - PubMed
  4. J Infect Dis. 2014 Jan 15;209(2):183-91 - PubMed
  5. J Pharmacol Sci. 2011;117(4):275-85 - PubMed
  6. J Neurosci. 2011 Nov 2;31(44):15650-9 - PubMed
  7. Parkinsonism Relat Disord. 2011 Nov;17 Suppl 1:S28-33 - PubMed
  8. J Physiol. 2013 Feb 15;591(4):1017-29 - PubMed
  9. Front Cell Neurosci. 2013 Feb 14;7:12 - PubMed
  10. Curr Opin Pharmacol. 2009 Jun;9(3):326-35 - PubMed
  11. Trends Biochem Sci. 2002 Nov;27(11):552-8 - PubMed
  12. Front Cell Neurosci. 2013 May 17;7:74 - PubMed
  13. Neurology. 2008 May 6;70(19):1691-8 - PubMed
  14. J Physiol. 2013 Feb 15;591(4):749 - PubMed
  15. Infect Immun. 2013 Oct;81(10):3894-902 - PubMed
  16. Brain. 2013 May;136(Pt 5):1555-67 - PubMed
  17. Neuroscience. 2005;134(1):175-87 - PubMed
  18. J Clin Microbiol. 2009 Jul;47(7):2349-50 - PubMed
  19. Toxicon. 2009 Oct;54(5):593-9 - PubMed
  20. Neurochem Int. 2012 Jul;61(2):236-9 - PubMed
  21. Neuroscience. 2011 Jul 14;186:201-7 - PubMed
  22. PLoS One. 2012;7(1):e29803 - PubMed
  23. Eur J Pharmacol. 2009 Sep 1;617(1-3):48-53 - PubMed
  24. Toxicon. 2010 Dec;56(8):1315-26 - PubMed
  25. Neurology. 2008 May 6;70(19):1707-14 - PubMed
  26. Neurology. 1997 Feb;48(2):456-64 - PubMed
  27. JAMA. 2011 Jan 5;305(1):89-90 - PubMed
  28. J Clin Microbiol. 1996 Aug;34(8):1934-8 - PubMed
  29. J Mol Biol. 2006 Sep 29;362(4):733-42 - PubMed
  30. J Neurosci. 2008 Apr 2;28(14):3689-96 - PubMed
  31. Traffic. 2012 Aug;13(8):1083-9 - PubMed
  32. Toxicon. 2009 Nov;54(6):857-61 - PubMed
  33. Eur J Pharmacol. 2010 May 10;633(1-3):10-4 - PubMed
  34. J Comp Neurol. 2001 Oct 1;438(4):388-98 - PubMed
  35. J Physiol. 2013 Feb 15;591(4):1031-43 - PubMed
  36. Mov Disord. 2013 Nov;28(13):1775-83 - PubMed

Publication Types